Drug Approvals

Pharmaceutical company receives FDA approval for levothyroxine sodium tablets

Published in Medical Letter on the CDC and FDA, August 15th, 2004

Mylan Laboratories Inc. (MYL) announced that the U.S. Food and Drug Administration has granted approval for the company to market its currently approved Levothyroxine Sodium Tablets as a bioequivalent and therapeutically equivalent (i.e., AB-rated) product to Jones Pharma Inc.'s Levoxyl Tablets.

The Mylan product is currently available to the trade in 0.025 mg, 0.050 mg, 0.075 mg, 0.088 mg, 0.1 mg, 0.112 mg, 0.125 mg, 0.150 mg, 0.175 mg, 0.2 mg and 0.3 mg strengths.

Mylan is the first company to offer Levothyroxine Sodium Tablets as AB-rated to Levoxyl, Unithroid and Synthroid.

Mylan Laboratories Inc. is a pharmaceutical company...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-08-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry